Prescription drug costs for millions of Americans with Medicare coverage are getting a lot cheaper in 2025.
New cost-saving provisions of the Inflation Reduction Act took effect Wednesday for Medicare enrollees. Chief among them: Out-of-pocket costs for prescription drugs are now capped at $2,000 through Medicare Part D, the optional prescription plan associated with the federal insurance program for people over 65 and younger Americans with disabilities.
“Before I took office, people with Medicare who took expensive drugs could face a crushing burden, paying $10,000 a year or more in copays for the drugs they need to stay alive,” President Joe Biden said in a statement Tuesday, touting the benefits of one of the largest legislative packages of his presidency. “This week, we take another step closer to an America where everyone can afford the quality health care they need.”
According to the Centers for Medicare & Medicaid Services (CMS), about 66 million Americans are enrolled in Medicare, and about 52 million of them have Part D prescription coverage. Most enrollees spend far less than $2,000 a year on their prescriptions, but officials estimate the new cap will help 19 million people save an average of $400 a year.
The cap works automatically. Once someone’s out-of-pocket drug expenses total $2,000 in one year, they won’t need to pay anything else for the rest of the year. For folks who meet that threshold early in the year, prescription drug costs can now be broken up into payments over the course of the year instead of when they happen to make the charges easier to manage.
Typical monthly premiums for Part D — which do not apply toward the out-of-pocket limit — are about $37 in 2025.
Other ways prescription drug costs are going down
“Substantial relief from high drug prices” is on the way for people with Medicare, CMS Administrator Chiquita Brooks-LaSure said in a statement.
That’s because in addition to the out-of-pocket cap for the Part D plan, dozens of drugs are getting cheaper in 2025 for enrollees with health insurance coverage through Part B. A separate provision of the Inflation Reduction Act helps Medicare beneficiaries when drugmakers hike prices above the rate of inflation.
CMS says that pharmaceutical companies did this for 64 drugs, including treatments for cancer, osteoporosis, and substance use disorder, and as a result must pay Medicare a rebate for the price hikes. The rebates will go toward subsidizing the cost of the affected drugs for enrollees through March 31. Each quarter, CMS re-calculates which drugs are included in the rebate program.
Over 853,000 people in Part B will benefit from the quarterly rebate starting this month, CMS says, with some saving as much as $10,818 per day for specialty drugs.
“This will be life-changing for people who have been living with high drug costs,” Brooks-LaSure said.
Already, the Inflation Reduction Act has capped insulin costs for Medicare beneficiaries at $35 a month, and that will remain in effect throughout 2025.
Beginning in 2026, lower prices for 10 drugs used to treat diabetes, arthritis, heart failure, cancer and other conditions will go into effect after Medicare negotiated with drugmakers for the first time ever. The out-of-pocket savings for Americans are expected to total $1.5 billion next year, and the cheaper drugs will save the Medicare program $6 billion.
Later this year, Medicare is expected to finalize the next batch of drugs to negotiate — 15 this time — and the new prices for them will go into effect in 2027.
More from Money:
Over 2 Million People to Get Increased Social Security Benefits Under New Law
The Best Over-the-Counter Drugs
According to a report from The Money.com, Medicare enrollees can expect significant cost savings on prescription drugs starting in 2025. The Inflation Reduction Act, which went into effect on Wednesday, includes provisions that will cap out-of-pocket costs for prescription drugs at $2,000 through Medicare Part D. This optional prescription plan is associated with the federal insurance program for people over 65 and younger Americans with disabilities.
President Joe Biden praised the new legislation, stating that it will provide relief for millions of Americans who previously faced high out-of-pocket costs for their medications. The Centers for Medicare & Medicaid Services (CMS) estimates that the new cap will help 19 million people save an average of $400 per year. This cap will automatically kick in once an individual’s out-of-pocket expenses reach $2,000 in a year, providing much-needed financial relief.
In addition to the out-of-pocket cap, the Inflation Reduction Act also includes a provision that will lower the cost of dozens of drugs for Medicare beneficiaries with Part B coverage. This is due to a separate provision that requires pharmaceutical companies to pay a rebate to Medicare when they increase drug prices above the rate of inflation. This will result in lower costs for treatments for conditions such as cancer, osteoporosis, and substance use disorder.
CMS Administrator Chiquita Brooks-LaSure stated that this legislation will provide “substantial relief from high drug prices” for people with Medicare. The rebates from drugmakers will go towards subsidizing the cost of affected drugs for enrollees through March 31, with CMS recalculating which drugs are included in the rebate program each quarter. Over 853,000 people in Part B will benefit from the quarterly rebate, with some saving up to $10,818 per day for specialty drugs.
Overall, the Inflation Reduction Act is expected to make a significant impact on the cost of prescription drugs for Medicare enrollees, providing much-needed financial relief for millions of Americans.
Source:Read More